Drug - Relistor® (methylnaltrexone bromide) Subcutaneous Injection [Wyeth]
October 2012
Therapeutic Area - Opioid-induced constipation
Relistor is indicated for the treatment of opioid-induced constipation in patients with advanced illness who are receiving palliative care, when response to laxative therapy has not been sufficient. Use of Relistor beyond four months has not been studied.
Relistor is contraindicated in patients with known or suspected mechanical gastrointestinal obstruction.
Patient Weight - Pounds | Patient Weight - Kilograms | Dose |
84 to < 136 | 38 to less than 62 | 8 mg (0.4 mL) |
136 to 251 | 62 to 114 | 12 mg (0.6 mL) |
< 84 OR > 251 | More than 114 | 0.15 mg/kg (more than one vial may be needed for patients >251 pounds) |
In patients with severe renal impairment (creatinine clearance less than 30 mL/min), dose reduction by one-half is recommended.
How Supplied
NDC NUMBER | PACK SIZE | CONTENTS |
65649-551-02 | 1 vial per carton | One 12 mg/0.6 mL single-use vial |
65649-553-05 | 7 trays per kit | Each tray contains:
one 12 mg/0.6 mL single-use vial, one 1 cc (mL) syringe with retractable (27-gauge x ½-inch) needle (VanishPoint®), two alcohol swabs |
65649-552-04 | 7 pre-filled syringes per carton | Seven 8 mg/0.4 mL single-use pre-filled syringes with needle guard system |
65649-551-03 | 7 pre-filled syringes per carton | Seven 12 mg/0.6 mL single-use pre-filled syringes with needle guard system |
QL = quantity limit; QL overrides allowed for dosing > QOD or pt wt > 251 pounds
MHCP Provider Call Center 651-431-2700 or 800-366-5411